Hormonal changes in inflammatory bowel disease

Česká verzia

Authors: Jana Kollerová; Tomáš Koller; Tibor Hlavatý; Juraj Payer
Authors place of work: V. interná klinika LF UK a UN Bratislava, Slovenská republika, prednosta prof. MUDr. Juraj Payer, PhD. MPH. FRCP.
Published in the journal: Vnitř Lék 2015; 61(Suppl 5): 35-39
Category: Reviews

Summary

Inflammatory bowel disease is often accompanied by extraintestinal manifestations due to a common autoimmune etiopathogenesis, chronic systemic inflammation, frequent nutrition deficits, and the treatment. Endocrine system changes belong to manifestations too. Interaction is mutual, Crohn´s disease and ulcerative colitis cause functional and morphological changes of endocrine tissues. On the other hand the endocrine disorders negatively influence the course of bowel disease. In the article we analyze correlation of IBD with gonadal hormone production and fertility, with adrenal function, with the function and morphology of the thyroid, with growth hormone production and growth disorders in children, and with bone mineral density reduction. This topic is not studied enough and needs more analysis and clarification.

Key words:
Crohn´s disease – endocrine system – inflammatory bowel disease – ulcerative colitis

Zdroje

1. Payer J, Huorka M, Duris I et al. Circadian rhythmicity and cross correlation of plasma gastrin, cortisol and somatostatin levels in ulcerative colitis patients and healthy subjects. Hepatogastroenterology 1993; 40(3): 272–275.

2. Payer J, Huorka M, Duris I et al. Cortisol and diseases of the gastrointestinal tract. Vnitř Lék 1995; 41(10): 696–698.

3. Huorka M, Payer J, Duris I et al. Hladina katecholamínov v moči u pacientov s ulceróznou kolitídou. Cs Gastroent Vyz 1990; 4(1)4: 31–34.

4. Strauss JF, Barbieri R. Yen & Jaffe´s Reproductive Endocrinology, Physiology, Pathophysiology, and Clinical Management. 7th ed. Saunders: 2013. ISBN 978–1455727582.

5. Bharadwaj S, Kulkarni G, Shen B. Menstrual cycle, sex hormones in female inflammatory bowel disease patients with and without surgery. J Dig Dis 2015; 16(5): 245–255.

6. Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994; 8(1): 83–100.

7. Knauff EAH, Eijkemans MJC, Lambalk CB et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009; 94(3): 786–792.

8. Fréour T, Miossec C, Bach-Ngohou K et al. Ovarian reserve in young women of reproductive age with Crohn’s disease. Inflamm Bowel Dis 2012; 18(8): 1515–1522.

9. Winger EE, Reed JL, Ashoush S et al. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol 2009; 61(2): 113–120.

10. Mahmood S, Nusrat S, Crosby A et al. Assessment of sexual function among inflammatory bowel disease patients. Am J Gastroenterol 2015; 110(4): 601–603.

11. Waljee A, Waljee J, Morris AM et al. Three fold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55(11): 1575–1580.

12. Arkuran C, McComb P. Crohn’s disease and tubal infertility: the effect of adhesion formation. Clin Exp Obstet Gynecol 2000; 27(1): 12–13.

13. Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol 2012; 25(1): 37–44.

14. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003; 3(1)1: 141–145.

15. Sidoroff M, Kolho KL. Screening for adrenal suppression in children with inflammatory bowel disease discontinuing glucocorticoid therapy. BMC Gastroenterol 2014; 14: 51. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–230X-14–51>.

16. Straub RH, Herfarth H, Falk W et al. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease? J Neuroimmunol 2002; 126(1–2): 116–125.

17. Straub RH, Vogl D, Gross V et al. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998; 93(11): 2197–2202.

18. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54(10): 1481–1491.

19. Stasi C, Orlandelli E. Role of the brain-gut axis in the pathophysiology of Crohn’s disease. Dig Dis 2008; 26(2): 156–166.

20. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988; 95(6): 1523–1527.

21. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18(2): 165–173.

22. Katsanos KH, Tsatsoulis A, Christodoulou D et al. Reduced serum insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 levels in adults with inflammatory bowel disease. Growth Horm IGF Res 2001; 11(6): 364–367.

23. Slonim AE, Bulone L, Damore MB et al. A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 2000; 342: 1633–1637.

24. Varille V, Cézard JP, de Lagausie P et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1996; 23(1): 13–19.

25. Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119(4): 895–902.

26. Bianchi GP, Marchesini G, Gueli C et al. Thyroid involvement in patients with active inflammatory bowel diseases. Ital J Gastroenterol 1995; 27(6): 291–295.

27. Shah SA, Peppercorn MA, Pallotta JA. Autoimmune (Hashimoto’s) thyroiditis associated with Crohn’s disease. J Clin Gastroenterol 1998; 26(2): 117–120.

28. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124(3): 795–841.

29. Leichtmann GA, Bengoa JM, Bolt MJ et al. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr 1991; 54(3): 548–552.

30. Pappa HM, Grand RJ, Gordon CM. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006; 12(12): 1162–1174.

31. Hlavaty T, Krajcovicova A, Koller T et al. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J Gastroenterol 2014; 20(42): 15787–15796.

32. Krajcovicova A, Hlavaty T, Killinger Z et al. Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients. J Crohns Colitis 2014; 8(12): 1693–1701.

33. Schoon EJ, Müller MC, Vermeer C et al. Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: another pathogenetic factor of osteoporosis in Crohn’s disease? Gut 2001; 48(4): 473–477.

34. Veerappan SG, O’Morain CA, Daly JS et al. Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33(12): 1261–1272.

35. Moschen AR, Kaser A, Enrich B et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54(4): 479–487.

36. Mazziotti G, Angeli A, Bilezikian JP et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006; 17(4): 144–149.